ReviewHeart rhythm O22026
Pulsed field ablation for ventricular arrhythmias: From mechanistic foundations to clinical translation.
Review in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ventricular pulsed field ablation from bench to bedside: preclinical and clinical evidence from a systematic review and meta-analysis.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Pooled it
- Ablation Methods and Catheter Settings for Ventricular Tachycardia Ablation: A Bench to Bedside Review: Part 2.Arrhythmia & electrophysiology review · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ventricular arrhythmias (VAs), particularly scar-related ventricular tachycardia, remain a leading cause of sudden cardiac death in patients with structural heart disease. Although radiofrequency ablation is the current standard of care, its efficacy is limited in complex myocardial substrates. Pulsed field ablation (PFA), a non-thermal and cell-selective technique based on irreversible electroporation, has emerged as a promising alternative. This review provides a comprehensive overview of the mechanistic rationale, preclinical validation, and early clinical experiences of PFA in VAs. It primarily discusses potential challenges in the clinical treatment of ventricular tachycardia. Furthermore, we highlight emerging catheter systems and the possible synergistic value of functional substrate mapping, preprocedural imaging, and parameter optimization in improving the precision and safety of PFA. As a promising ablation technology, PFA holds strong potential for treating VAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.